Nivolumab plus ipilimumab for advanced kidney cancer after progression on immunotherapy
This phase 2 study looked at the effect on survival [...]
Ipilimumab-nivolumab and axitinib-pembrolizumab combinations produce similar survival times
When ipilimumab plus nivolumab or axitinib plus pembrolizumab are used [...]
A modified nivolumab/ipilimumab dosing regimen
In this phase 3b/4 study, people with advanced kidney cancer [...]
ESMO 2022: Nivolumab before and after surgery to prevent recurrence of kidney cancer
In this phase 3 randomised study, presented at the European [...]
ESMO 2022: Combination of cabozantinib, nivolumab and ipilimumab for patients with advanced kidney cancer with high-risk disease
The results of COSMIC-131 were presented at the European Society [...]
Neutrophil-eosinophil ratio predicts response of kidney cancer to ipilimumab plus nivolumab
Neutrophils and eosinophils are white blood cells. In this study, [...]
Nivolumab plus ipilimumab for localised kidney cancer
In a recent phase 3 clinical trial the combination of [...]
Adjuvant nivolumab plus ipilimumab for kidney cancer
Adjuvant therapy is medication that is given after surgery to [...]
Nivolumab compared to cabozantinib as a second- or third-line treatment
This study looked at real world data from people with [...]
Cabozantinib plus nivolumab and ipilimumab delays progression in kidney cancer
Preliminary results from the COSMIC-313 clinical trial have ben released. [...]
